MedTrace Logo

Evaluation of Health Costs and Resource Utilization

NCT01960426 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2016-05-13

No results posted yet for this study

Summary

Utilization of health resources in a testing based strategy versus an empiric dose escalation strategy to manage Crohn's disease and Ulcerative Colitis in subjects with loss of response to infliximab or adalimumab.

Conditions

Interventions

OTHER

Measurement of drug (Adalimumab/Infliximab)

Measurement of drug (adalimumab/infliximab) and ADAs in the presence of drug.

OTHER

Intensify treatment with the existing drug

Intensify treatment with the existing drug and if this fails empirically switch to another TNF antagonist

Sponsors & Collaborators

  • Prometheus Laboratories

    collaborator INDUSTRY

  • University of Western Ontario, Canada

    lead OTHER

Principal Investigators

  • Brian Feagan, MD · Robarts Clinical Trials Inc. - Western University

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01960426 on ClinicalTrials.gov